The Prognostic Values of the Insulin-Like Growth Factor Binding Protein Family in Ovarian Cancer

Table 2

The prognostic value of the IGFBP2 mRNA expression in ovarian cancer.

	Overall survival			Progression-free survival
	Cases	HR (95% CI)	value	Cases	HR (95% CI)	value
Histology
All cancer patients	1656	1.13 (0.99−1.29)	0.081	1435	1.17 (1.03−1.33)	0.014
Serous cancer patients	1207	0.87 (0.74−1.02)	0.079	1104	1.13 (0.98−1.3)	0.098
Endometrioid cancer patients	37	4.93 (0.55−44.16)	0.11	51	2.67 (1.05− 6.79)	0.032
Pathological grades
I	56	0.55 (0.22−1.42)	0.21	37	1.76 (0.58−5.41)	0.31
II	324	1.31 (0.95−1.8)	0.096	256	1.21 (0.9−1.63)	0.2
III	1015	0.86 (0.73−1.02)	0.088	837	1.07 (0.91−1.27)	0.41
Clinical stages
I and II	135	1.68 (0.77−3.67)	0.19	163	2.16 (1.1−4.25)	0.022
III and IV	1220	1.11 (0.95−1.28)	0.18	1081	0.91 (0.78−1.07)	0.27
Chemotherapy
Contains platin	1409	1.2 (1.03−1.39)	0.02	1259	1.12 (0.98−1.27)	0.087
Contains taxol	793	1.16 (0.95−1.41)	0.16	715	0.91 (0.75−1.11)	0.35
Contains taxol+platin	776	1.15 (0.94−1.41)	0.17	698	1.08 (0.91−1.29)	0.38

.